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Phosphotyrosine phosphatases (PTPs) serve as important regulators of cellular signal transduction
pathways. PTPs are sensitive targets of oxidative stress and may be inhibited by treatments that
induce intracellular oxidation. The effects of PTP inactivation under oxidizing conditions are
amplified by the redox-linked activation of key protein tyrosine kinases (PTKs), thus leading to the
initiation of phosphotyrosine-signaling cascades that are no longer under normal receptor control.
These ligand-independent signals result in the accumulation of protein phosphotyrosine, the
generation of second messengers, the activation of downstream kinases, and the nuclear
translocation of nuclear factor kappa B (NF-KB). In this review we consider the relative contribution
of oxidative stress to the effects of PTP inhibition by vanadium-based compounds in lymphocytes.
Although the inactivation of PTPs can lead to NF-KB mobilization in the presence of antioxidants,
the other effects noted appear to require a threshold of intracellular oxidation. The combined
effects of oxidative stress on signal transduction cascades reflect a synergy between the initiation
of signals by PTKs and the loss of control by PTPs. This suggests a mechanism by which
environmental agents that cause oxidative stress may alter the course of cellular responses
through induction or enhancement of signaling cascades leading to functional changes or cell
death. Environ Health Perspect 106(Suppl 5):1 179-1184 (1998). http.//ehpnet1.niehs.nih.gov/
docs/1998/Suppl-5/1 179-1184krejsa/abstracthtml
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Introduction
The role of aberrant signal transduction
in chemical toxicity is emerging as an
important area of environmental health
research. In particular, numerous studies
have shown that oxidative stress, induced
by chemical prooxidants or ionizing radia-
tion, can result in ligand-independent
stimulation of cellular phosphorylation
pathways. Oxidative stress results from an
excess of reactive oxygen species (ROS)
within the cell, which overwhelms the
capacity of cellular antioxidant systems,
leading to damage ofcellular macromole-
cules (1). Oxidative stress can result from
generation of ROS by the biochemical
interactions ofthe prooxidant, as seen in
the case of metal redox cycling, or from
depletion of cellular antioxidants, which
allows endogenously produced ROS to
increase to toxic levels, as seen after glu-
tathione (GSH) depletion by some alkylat-
ing agents (2,3). In addition, mechanisms
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exist for the induction ofoxidative stress at
sites of inflammation as a part of host
defense (4). A growing body ofliterature
suggests that changes in intracellular redox
status may be an essential part of normal
signal transduction control; therefore,
shifting the balance of cellular oxidative
stress may co-opt redox-sensitive pathways
and alter the fate ofthe cell. In light ofthis
hypothesis, significant effort has been com-
mitted to identifying redox-sensitive signal
transduction pathways and the cellular
effects oftheir perturbation.
As mechanisms ofsubacute toxicity are
established, the epigenetic effects ofoxida-
tive stress are being strongly implicated in
the development ofdiseases including ath-
erosclerosis, autoimmunity, neurodegener-
ative disorders, and cancer (5-8). The
activation ofsignaling pathways and the
induction of suites of genes by oxidative
stress can alter the functional development
of affected cells, leading to such diverse
outcomes as cellular proliferation and pro-
grammed cell death (9). Increasingly, toxi-
cologists are working to understand these
epigenetic effects in the context of normal
signal transduction control by key kinases,
phosphatases, and transcription factors.
Since many environmental toxicants exert
their effects through an oxidative mecha-
nism, the induction of intracellular oxida-
tive stress can serve as a general model for
the impact of several classes of chemicals
on signal transduction.
The activation oftyrosine phosphoryla-
tion pathways by oxidative stress has been
the subject of much investigation (for
reviews see Schieven and Ledbetter (10),
Schieven (11), and Suzuki et al. (12)].
Oxidative stress in many cell types can
activate kinases, induce Ca2+ influx, and
stimulate the nuclear mobilization oftran-
scription factors (12). Our research has
focused on the action ofoxidative stress in
lymphocytes. Several key kinases, including
the srcfamily kinase Lck, which is essential
for mediating T-cell receptor signals, and
the downstream kinases Syk and ZAP-70,
are activated by treatments that induce
intracellular oxidation. These signaling cas-
cades result in the generation of second
messengers, including intracellular Ca2+
and inositol 1,4,5-triphosphate, and lead to
the mobilization ofthe important transcrip-
tion factor NF-KB (13-16). Our recent
work has focused on a role for impairment
of phosphotyrosine phosphatase (PTP)
function in many of these effects (17,18).
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We have used vanadium-based compounds
to investigate the differential effects of
PTP inhibition and oxidative stress in the
activation oflymphocytesignalingpathways.
Vanadium is a transition metal of
environmental health concern, as chronic
respiratory exposures are common in the
steel, mining, petrochemical, and utilities
industries. Epidemiologic evidence indicates
that workers exposed to vanadium in fumes
and particulates develop bronchopulmonary
diseases, increased pulmonary infections,
andlung cancer (19). Rats exposed by intra-
tracheal infusion to vanadium salts or resid-
ual oil fly ash, an industrial particulate
containing high levels ofvanadium, exhib-
ited pulmonary inflammation, increased
chemokine production, and altered cytokine
responses compared with controls (20,21).
Subacute tests with rats exposed to ammo-
nium metavanadate (NH4VO3) in aerosol
form suggest that these effects are due to
alterations in pulmonary macrophage func-
tion (19). The contribution of tyrosine
phosphatase inhibition and oxidative stress
to these effects has not yet been established,
although current understanding ofinflam-
matory processes suggests that both factors
may be important. Vanadium compounds
have also been used therapeutically as com-
ponents ofmetal alloys in joint-replacement
prosthetics, and are currently being investi-
gated for the treatment ofinsulin-resistant
diabetes mellitus (22,23). The action of
vanadium as a PTP inhibitor is thought to
be responsible for its ability to mimic
insulin in vivo(23).
PTP Control in Lymphocyte
Signal Transduction
In lymphocytes, the PTPs act as both
positive and negative regulators ofsignal
transduction (24). For example, the mem-
brane-bound PTP CD45 dephosphorylates
the negative regulatory tyrosine on Lck,
allowing the kinase to adopt an active con-
formation and initiate T-cell antigen recep-
tor (TCR) signals (25). CD45 also exerts
negative control by dephosphorylation of
the TCR 4 chain and the associated kinase
ZAP-70 (24,26). The src homology (SH2)
domain containing PTPs SHP-1 and SHP-
2 also plays an important role in signal ter-
mination from a variety of receptors on
cells of both lymphoid and myeloid lin-
eages. SHP-1 in particular was found to be
defective in the motheaten mouse, resulting
in the severe inflamation and lymphoprolif-
erative disorder seen in that phenotype
(27). Other PTPs and dual-specificity
phosphatases exert control on downstream
pathways, acting on the regulatory tyrosines
of Rafl, SHC, erkl, erk2, JNK, and vari-
ous transcription factors (28-33). While
the discovery ofimportant PTPs has lagged
behind that oftyrosine kinases, it is clear
that PTPs perform crucial functions in the
orchestration ofimmune responses in vitro
and in vivo [reviewed byNeel (34)].
Biological Effects of PTP
Impairment
Studies with the motheaten mouse have
demonstrated that SHP-1 impairment
causes a failure in signal termination from
the antigen receptors on lymphoid cells,
leading to hypergammaglobulinemia and
severe lymphoproliferative disorder (27,34).
CD45-negative cell lines and mice have
been generated; these show alackofrespon-
siveness to antigen-receptor signals, resulting
in deficits in thymocyte development, and
T-cell-mediated immune responses, per-
turbed B-cell development, and impaired
B-cell proliferation (34). Clinical studies
with CD4+ T cells from HIV+ patients
showed reduced CD45 activity and failure
to proliferate compared to noninfected con-
trols; these deficits could be alleviated by
culturing the cells with antioxidants (35).
This suggests that oxidative stress plays a
role in the loss ofT-cell function seen in
HIV+ patients. Treatment ofT-cells or
macrophages with peroxovanadium PTP
inhibitors also induced activation ofthe
HIV-1 long terminal repeat and production
ofvirions in infected cells (36,37).
PTPs and Oxidative Stress
The active sites of the PTPs and dual-
specificity phosphatases contain an acidic
cysteine that must remain in reduced form
for catalysis to occur. Briefly, the cysteine
exerts a nudeophiic attack on the phospho-
rous ofa phosphotyrosine substrate, result-
ing in the formation ofa thiol-phosphate
intermediate. The reaction is completed by
hydrolysis and the cysteine is regenerated
with water as the electron donor (38).
PTPs are sensitive targets ofoxidative stress,
and many of the best PTP inhibitors are
sulfhydryl reactive agents (39,40). While
the PTP active site appears to be deeply
buried in the protein, its microenvironment
is sensitive to intracellular oxidation.
Approximately 80% of PTP activity in
hepatocytes is sensitive to hydrogen perox-
ide (H202) treatment (40). In addition to
determining substrate specificity, the
arrangement of residues surrounding the
PTP active site may also confer more or less
sensitivity to oxidative stress.
Although many agents that induce
oxidative stress may inhibit PTPs, it is of
interest to compare treatments with differ-
ent oxidative potentials to assess the relative
contribution ofintracellularoxidation to the
action ofthe PTP inhibitors. For example,
neither the PTP inhibitor sodium ortho-
vanadate (Na3VO4) nor H202 alone can
activate the protein tyrosine kinase (PTK)
Lck, but treatment oflymphocytes with
both agents together results in the strong
Lck activation (13). Similarly, treatment of
lymphocytes with Na3VO4 or another PTP
inhibitor, molybdate, has averyminoreffect
on the Janus Kinase (Jak)/STAT (signal
transducers and activators oftranscription)
pathways, which mediate cytokine signaling
in lymphocytes; however the peroxoderiva-
tives ofthese metals are extremely effective
activators ofthe Jak/STAT pathways (33).
There is evidence that vanadium and other
transition metals maybe oxidized intracellu-
larly through redox cycling with NADPH
(2,33,41). The generation ofROS in these
redox cycles may be an important mecha-
nism by which metals induce toxicity and
may increase the susceptibility ofPTPs by
lowering the cellular pool ofGSH and other
reducing agents (2). Because oxidizing con-
ditions can both inhibit PTPs and activate
PTKs, the strong induction ofsignaling cas-
cades by PTP inhibitors that also induce
oxidative stress is likely to result from syner-
gistic activation ofthe signaling molecules
and the loss ofregulation byPTPs.
Studieswith Vanadium
PTP Inhibitors
Pharmacologic PTP inhibitors have been
widely used as probes to understand the
role ofphosphotyrosine signaling in lym-
phocytes, and numerous studies have
shown that disruption ofPTP control over
signal transduction networks by phar-
macologic agents alters lymphocyte func-
tion. Our recent studies focus on the role of
oxidative stress in the action of PTP
inhibitors, using vanadium-based com-
plexes as model compounds. To differenti-
ate the effects ofdirect PTP inhibition from
other possible effects ofoxidative stress, we
have chosen three vanadium compounds
that exhibit similar inhibition of major
PTPs such as CD45 and PTP lB in direct
assays but differ markedly in their ability to
induce oxidative stresswithin thecell.
Vanadium compounds have been
widely used as PTP inhibitors, and their
efficacy has been demonstrated in animal
models and human clinical trials of
insulin-resistant diabetes mellitis (23).
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Different ligation ofvanadium compounds
enhances the action ofthe vanadium, stabi-
lizes the vanadium in a particular oxidation
state, and targets the compound to different
tissues (42,43). Many studies have shown
that pervanadate is an extraordinarily effec-
tive activator ofcellular tyrosine phospho-
rylation in a wide variety of cells (11).
Recent studies elucidated the mechanism of
pervanadate action. Unlike vanadate, which
acts as a reversible transition-state analogue
ofphosphate, pervanadate can also oxidize
the PTP catalytic site cysteine to form cys-
teic acid, which cannot be reduced to
regenerate an active enzyme (44). The rate
ofthis reaction may vary between different
PTPs, since in our hands PTP-1B activity
following pV(phen) treatment could be
partially restored by the reducing agents
dithiothreitol or ,-mercaptoethanol,
whereas CD45 activity was irreversibly lost
(18). This suggests that the effects ofa par-
ticular metal-ligand complex on cellular
PTP activity depend on both its affinity for
specific PTP targets and the sensitivity of
these targets to thiol oxidation.
A comparison of three structurally
different vanadium-based PTP inhibitors
on PTP-1B activity in vitro is shown in
Figure 1. Na3VO4,bis(maltolato)-oxovana-
dium(VI) (BMOV), and sodium oxodiper-
oxo(1,10-phenanthroline)vanadate(V)
(pV(phen) were used for this study. These
compounds differ in their ability to induce
intracellular oxidative stress, as measured by
fluorescence ofdichlorofluorescein (DCF),
an intracellularlylocalized indicator ofoxida-
tive stress, in lymphocytes treated with
equimolar amounts ofthe three inhibitors.
Na3VO4 induced no intracellular oxidation,
BMOV induced minor oxidation, and
pV(phen) strongly increased the level of
DCF-detectable intracellular oxidation com-
pared to that in untreated controls. Con-
sistent with the mechanism of action
proposed for pervanadate, the pV(phen), a
stabilized peroxovanadium complex, irre-
versibly inhibited the PTP-1B, whereas PTP
activity was restored if the Na3VO4- or
BMOV-treated enzyme was washed to
remove the inhibitor prior to assay. Recovery
ofPTP activity in the Na3VO4- or BMOV-
treated enzyme upon washing demonstrated
that the mechanism of inhibition was
reversible forthese compounds in contrast to
inhibition bytreatmentwith pV(phen)(18).
In another set of experiments, CD45
was immunoprecipitated from T cells
treated with pV(phen) or from cells that
had been pretreated with the antioxidant
pyrrolidine dithiocarbamate (PDTC)
before pV(phen) treatment. CD45 activity
was partially preserved in cells pretreated
with PDTC, whereas cells treated with
pV(phen) alone had no CD45 activity
(18). This suggests that the antioxidant
protected CD45 from irreversible inactiva-
tion by pV(phen) in cells. However, in
direct assays, pV(phen) was an effective
inhibitor ofPTP-1B and CD45 in the pres-
ence ofantioxidants (18). Further study of
CD45 inactivation in pV(phen)-treated
cells revealed that the PTP was totally
inhibited at the earliest timepoint tested
(Figure 2A), whereas the accumulation of
protein phosphotyrosine lagged behind
CD45 inhibition. It has been shown previ-
ously that peroxovanadium compounds do
not directly activate PTKs in in vitro kinase
assays (13,15,18). Therefore, we examined
the relationship between the development
ofoxidative stress and the accumulation of
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Figure 2. Intracellular phosphotyrosine accumulation
is delayed with respect to CD45 inhibition. (A) CD45
activity from Jurkat T cells treated with 25 pM
pV(phen) for 30 to 120 min [Krejsa et al. ( 18)].
(B) Correlation between development of intracellular
oxidation and phosphotyrosine accumulation in Jurkat
cells treated with 25 pM pV(phen)for30 to 120 min.
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Figure 1. Structures and PTP-1B inhibition bythree vanadium-based PTP inhibitors. PTP-1B-GST-agarose was incu-
bated with 5 pM Na3VO4 (A), BMOV (B), or pV(phen) (C) and assayed for activity against p-nitrophenyl phosphate
as previously described (18). The enzyme-agarose was either washed with buffer containing 5 mM EDTA prior to
the assay ortested in the presence of 5 pM inhibitor.
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protein phosphotyrosine (18). Acorrelation
of phosphotyrosine accumulation with
intracellular oxidation, as detected by DCF
fluorescence, reveals a threshold effect, sug-
gesting that the activation ofkinases may
require the induction ofintracellular oxida-
tion (Figure 2B). These results may help to
distinguish effects typical ofkinase activa-
tion byoxidative stress from those mediated
solely by PTP inhibition; alternatively, they
may reflect the differential sensitivity ofkey
PTPs to intracellular oxidation, resulting in
a sequential loss ofcontrol over cellular
phosphorylation cascades as the oxidative
stress increases.
The accumulation ofphosphotyrosine
and activation ofdownstream kinases by
vanadium PTP inhibitors required a degree
ofintracellular oxidation and could be pre-
vented by PDTC (18). To further investi-
gate the synergy between intracellular
oxidation and PTP inhibition, we studied
the effect ofthe cellular reductant GSH on
the efficacy ofpV(phen) (Figure 3). GSH
synthesis can be inhibited by treatment of
cells with buthionine sulfoximine (BSO)
(45). After overnight BSO treatment to
deplete intracellular GSH, Ramos B cells
treated with pV(phen) showed increased
sensitivity to time-dependent (Figure 3A)
and dose-dependent (Figure 3B) phospho-
tyrosine accumulation. This supports a role
for endogenous cellular antioxidant sys-
tems in the preservation of PTP function
and suggests that intracellular thiol status
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could affect the activation ofkey kinases in
Ramos cells.
Although Na3VO4, BMOV, and
pV(phen) had equivalent potency in direct
PTP assays, there were marked differences
in their effects on intact lymphocytes. For
example, Na3VO4 had little effect on either
B or T lymphocytes, whereas BMOV and
pV(phen) had distinct effects on these two
cell types. BMOV induced apoptosis in B
cells but enhanced the activation ofT cells
(17). These effects occurred without the
induction ofsignificant intracellular oxida-
tion by BMOV. In contrast, pV(phen)
induced strong oxidative stress in both T
cells and B cells. The effects ofpV(phen)
on signal transduction resembled the
reported effects ofoxidative stress, includ-
ing the activation of PTKs, accumulation
of tyrosine phosphorylated proteins, and
activation oferk2. Much ofthe response
to pV(phen) was mitigated if the cells
were pretreated with PDTC before
pV(phen) treatment. Phosphotyrosine
accumulation was mimimal, the activation
of PTKs was greatly delayed and dimin-
ished, and the downstream kinase erk2
was not activated (18).
We have also examined the ability of
vanadium-based PTP inhibitors to induce
NF-iKB activation in T cells. Both BMOV
and pV(phen) activated NF-KB, even
though the BMOV treatment did not
induce intracellular oxidation (18). This
suggested that inhibition ofPTPs led to the
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Figure 3. GSH depletion enhances intracellular phosphotyrosine accumulation after PTP inhibition. Ramos B cells
were treated overnight with 100 pM BSO to deplete intracellular GSH before pV(phen) treatment. Cells were lysed
and immunoblotted and blots were stained for phosphotyrosine. (A) Cells treated with 25 pM pV(phen) for 1 to 4
hr.(B)Cells treated for2 hrwith pV(phen) at indicated doses.
activation ofNF-wB without a requirement
for intracellular oxidation. To further
address this finding, we pretreated T cells
with antioxidants and found that both
BMOV and pV(phen) still induced the
activation ofNF-icB (18). This confirms
that NF-KB, a transcription factor well
known for its sensitivity to oxidative stress,
can also be activated by PTP inhibition
independent ofintracellular oxidation (18).
Discussion
Because the PTKs and PTPs act in concert
to regulate phosphotyrosine-signaling
pathways, it has been difficult to separate
the effects ofoxidative stress mediated by
kinase activation from those caused by
phosphatase inhibition. In addition, some
of the end points commonly used to
observe the induction of cellular signals
by chemical agents are less sensitive to
oxidative stress than others. It is therefore
important to assay signaling pathways at
multiple points, including the proximal
activation ofkey kinases, the accumulation
ofphosphorylated substrates, and the acti-
vation ofdownstream signaling molecules
and important transcription factors that
integrate incoming messages into a cellular
response. Oxidative stress can induce
ligand-independent signals at each ofthese
levels (11).
Many studies using PTP inhibitors have
been undertaken with the goal ofidentify-
ing important phosphotyrosine signaling
pathways leading to changes in cellular
function, without attempts to distinguish
between effects ofoxidative stress on PTK
activation versus PTP inhibition. However,
from the point ofview oftoxicology, it is
desirable to understand the most sensitive
steps in these signalingpathways in order to
identify mechanisms by which agents that
induce oxidative stress may alter cellular
function and lead to tissue injury or disease.
Our investigations with vanadium-based
PTP inhibitors suggest that the effects of
PTK activation and PTP inhibition can be
distinguished, in that not all of the
observed effects ofPTP inhibition appeared
to require PTK activation. As the effects of
intracellular oxidation on signal transduc-
tion pathways are elucidated, particular
PTPs may emerge whose susceptibility
toward oxidative stress governs the cellular
response to environmental toxicants. The
identification ofPTPs and PTKs with dif-
ferential sensitivity to redox-regulated inhi-
bition or activation may in turn shed light
on the regulation ofcellular function by
endogenouslyproduced oxidants.
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Conclusion
Signal transduction requires the concerted
actions of a great many signaling mole-
cules, and small changes in the activity of
these molecules are amplified along signal-
ing cascades. Therefore the impairment of
function ofonly a few oxidation-sensitive
PTPs may result in a shift in the balance
of, phosphotyrosine along certain pathways
at the expense ofothers. Communication
between the cell surface and the nucleus
might be altered subtly at each level along
the signaling pathway, with message
fidelity progressively lost as the signal
passes on. In cases ofstronger oxidative
insult, the inhibition of PTPs synergizes
with the oxidative induction ofPTK activ-
ity, and signaling cascades normally under
receptor control are initiated in a ligand-
independent manner.
The long-term effects of oxidant
initiated signaling cascades in vivo are
unknown, but given the complexities of
lymphocyte receptor interactions and the
elaborate controls placed on induction of
immune responses, it is expected that oxi-
dant-induced signals will have detrimental
effects. The studies to date suggest that these
principles apply as well to other tissues in
which phosphorylation pathways control
cellular function. Oxidative stress has been
implicated the etiology ofa wide variety of
diseases, many ofwhich are believed to have
environmental causes. Further research is
needed to learn the mechanisms by which
lymphocytes resist oxidative stress, and to
identify effects ofenvironmental oxidants,
especially sulfhydryl-reactive transition met-
als, on the control ofsignal transduction
cascades byPTPs. Studies ofcellular interac-
tions and in vivo effects can enhance under-
standing ofhow oxidative stress can increase
susceptibility to immune disorders and
reveal possible strategies for prevention or
mitigation ofsuch illnesses.
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